Aromatase inhibitors and the treatment of breast cancer

Related Experiment Video

Updated: Aug 14, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

A M Brodie, L Y Wing, P Goss

    Journal of Steroid Biochemistry
    |January 1, 1986
    PubMed

    Insights

    Aromatase inhibitors like 4-OHA reduce estrogen production, offering a new treatment for postmenopausal breast cancer. Clinical trials show significant tumor regression in patients with advanced metastatic breast cancer.

    Area of Science:

    • Endocrinology
    • Oncology
    • Pharmacology

    Background:

    • Hormone-dependent breast cancer relies on estrogen for growth.
    • Aromatase inhibitors reduce estrogen production by peripheral and ovarian tissues.
    • C19, 17 keto steroids are potent aromatase inhibitors, causing rapid competitive inhibition and enzyme inactivation.

    Purpose of the Study:

    • To evaluate the efficacy of 4-OHA, a potent aromatase inhibitor, in treating postmenopausal women with advanced metastatic breast cancer.
    • To assess the impact of 4-OHA on estradiol levels and tumor response.

    Main Methods:

    • Animal studies in rats and monkeys demonstrated inhibition of aromatase activity and tumor regression.
    • Clinical trial involving 60 postmenopausal patients with advanced metastatic breast cancer treated with weekly injections of 4-OHA.
    • Estradiol levels and gonadotropin levels were monitored in patients.

    Main Results:

    • Injections of aromatase inhibitors successfully inhibited peripheral aromatization in monkeys and ovarian aromatase in rats, leading to mammary tumor regression.
    • In postmenopausal patients, 4-OHA significantly reduced mean estradiol levels to 36% of pretreatment values within 1 month.
    • Complete or partial tumor regression was observed in 30% of patients, with 15% showing static disease.

    Conclusions:

    • 4-OHA effectively inhibits peripheral aromatization in postmenopausal women.
    • The study suggests that 4-OHA is a valuable therapeutic agent for treating postmenopausal breast cancer, particularly in patients with advanced metastatic disease.

    More Related Videos

    Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

    Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

    Published on: June 18, 2015

    Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

    Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

    Published on: June 9, 2023

    Related Concept Videos

    Cancer Prevention02:59

    Cancer Prevention

    Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
    Some...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

    5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are typically...